Tokai Pharmaceuticals announces review of strategic alternatives
Friday, September 09, 2016
Tokai Pharmaceuticals announces review of strategic alternatives.
Tokai pharmaceuticals inc says board of directors has initiated a review of strategic alternatives for company focused on maximizing stockholder value.
Tokai Pharmaceuticals Inc says as part of its review of strategic alternatives, Tokai has engaged wedbush pacgrow as its financial advisor.
Tokai Pharmaceuticals Inc says in conjunction with this process, company is continuing to assess best path forward for its galeterone clinical trial program.
Says now anticipates all patients enrolled in ARMOR3-Sv clinical trial will discontinue treatment by end of year.
Now anticipates all patients enrolled in ARMOR3-SV clinical trial will discontinue treatment by end of year.
Source : reuters.com
